Acquired Company

AVROBIO acquired Tectonic Therapeutic in an all-stock merger completed June 20, 2024, with the combined company operating as Tectonic Therapeutic, Inc. and trading on Nasdaq under the ticker TECX.

Tectonic Therapeutic, Inc. is a biopharmaceutical company headquartered in Watertown, Massachusetts, dedicated to the innovative development of antibody-based therapies targeting G-protein-coupled receptors (GPCRs), essential components in numerous disease pathways. The company is committed to addressing significant unmet medical needs by providing new treatment alternatives for patients unresponsive to current therapies. With a robust and diverse pipeline of biologics under development, Tectonic is strategically positioned to lead advancements in drug development and contribute meaningfully to the therapeutic landscape. Show more

Location: 490 ARSENAL WAY, WATERTOWN, MA, UNITED STATES, 02472, Watertown, MA, 02472, USA | Website: https://tectonictx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

374.1M

52 Wk Range

$13.70 - $50.63

Previous Close

$19.99

Open

$19.96

Volume

427,455

Day Range

$19.96 - $23.12

Enterprise Value

106.9M

Cash

268.4M

Avg Qtr Burn

-17.82M

Insider Ownership

38.38%

Institutional Own.

69.59%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TX45 Details Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TX45 Details Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TX45 Details Pulmonary Hypertension (PH) associated with Interstitial Lung Disease (ILD)	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TX2100 Details Hereditary Hemorrhagic Telangiectasia (HHT)	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.